STC1 and colorectal carcinoma: In summary, our findings demonstrated that A20 promotes colorectal cancer immune evasion by upregulating STC1 expression to block membrane translocation of “eat-me” signal, which may represent a novel predictive biomarker for selecting CRC patients who are most likely to benefit from ICI therapy alone or its combination with other anticancer treatment.